Division of Cardiology, Azienda Ospedaliera-Universitaria Maggiore della Carità, Italy.
Department of Cardiology, UMC St Radboud, The Netherlands.
Eur J Prev Cardiol. 2016 Jun;23(9):931-7. doi: 10.1177/2047487315614493. Epub 2015 Nov 2.
Contrast-induced nephropathy is a common complication of procedures that are likely to use contrast media. The identification of high-risk patients and preventive optimal hydration are key measures to reduce the incidence of contrast-induced nephropathy. The aim of this study was to evaluate the role of the contrast volume to creatinine clearance ratio (V/CrCl) in the prediction of contrast-induced nephropathy after coronary angiography or percutaneous coronary intervention.
Our population consisted of 2308 consecutive patients undergoing coronary angiography and/or percutaneous coronary intervention. The risk of contrast-induced nephropathy was evaluated across quartiles of the V/CrCl. Receiver operating characteristic curves were used to identify the best predictive value. Contrast-induced nephropathy was defined as an absolute increase of 0.5 mg/dL or a relative increase of >25% in creatinine levels 24-48 hours after the procedure.
The total incidence of contrast-induced nephropathy was 12.2% and was significantly higher in the fourth quartile (first quartile 8.8%, second quartile 8.9%, third quartile 11.6% and fourth quartile 19.4%; P < 0.001). Using receiver operating characteristic curves we identified V/CrCl ≥ 6.15 as the best discriminant value for the prediction of contrast-induced nephropathy, which occurred in 25.1% of patients with V/CrCl ≥ 6.15 versus 9.7% in patients with V/CrCl < 6.15. These results were also confirmed at multivariate analysis after correction for all baseline confounders (adjusted odds ratio (AOR) (95% confidence interval (CI)) 1.81 (1.19-2.76); P = 0.005). The association between V/CrCl > 6.15 and an increased risk of contrast-induced nephropathy was confirmed among diabetic (11% vs. 27.7%; p P < 0.001) and non-diabetic patients (8.9% vs. 23%; Pp < 0.001), also after correction for all baseline confounders.
This is one of the largest studies evaluating the association between the V/CrCl ratio and the risk of contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous coronary intervention. We found that a V/CrCl ratio >6.15 was independently associated with an increased risk of contrast-induced nephropathy.
对比剂肾病是一种常见的使用对比剂的操作的并发症。识别高危患者和预防性最佳水化是降低对比剂肾病发生率的关键措施。本研究旨在评估对比剂体积与肌酐清除率比值(V/CrCl)在预测冠状动脉造影或经皮冠状动脉介入治疗后对比剂肾病中的作用。
我们的研究人群包括 2308 例连续接受冠状动脉造影和/或经皮冠状动脉介入治疗的患者。根据 V/CrCl 的四分位数评估对比剂肾病的风险。使用受试者工作特征曲线来确定最佳预测值。对比剂肾病定义为术后 24-48 小时肌酐水平绝对增加 0.5mg/dL 或相对增加>25%。
对比剂肾病总发生率为 12.2%,第四四分位组明显更高(第一四分位 8.8%,第二四分位 8.9%,第三四分位 11.6%,第四四分位 19.4%;P<0.001)。使用受试者工作特征曲线,我们确定 V/CrCl≥6.15 是预测对比剂肾病的最佳判别值,在 V/CrCl≥6.15 的患者中,对比剂肾病的发生率为 25.1%,而 V/CrCl<6.15 的患者中为 9.7%。这些结果在对所有基线混杂因素进行校正后的多变量分析中也得到了证实(校正后比值比(95%置信区间(CI))1.81(1.19-2.76);P=0.005)。在校正所有基线混杂因素后,V/CrCl>6.15 与糖尿病(11% vs. 27.7%;p P<0.001)和非糖尿病患者(8.9% vs. 23%;Pp<0.001)发生对比剂肾病的风险增加之间的相关性也得到了证实。
这是评估冠状动脉造影或经皮冠状动脉介入治疗患者 V/CrCl 比值与对比剂肾病风险之间关系的最大研究之一。我们发现,V/CrCl 比值>6.15 与对比剂肾病风险增加独立相关。